Rajeev Saggar
Chief Tech/Sci/R&D Officer bei LIQUIDIA CORPORATION
Vermögen: 3 Mio $ am 31.03.2024
Profil
Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0,28% | 19.04.2024 | 211 672 ( 0,28% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Rajeev Saggar
| Unternehmen | Position | Beginn |
|---|---|---|
| LIQUIDIA CORPORATION | Chief Tech/Sci/R&D Officer | 18.07.2022 |
Ehemalige bekannte Positionen von Rajeev Saggar
| Unternehmen | Position | Ende |
|---|---|---|
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01.07.2022 |
| The Banner-University Medical Center | Corporate Officer/Principal | - |
Ausbildung von Rajeev Saggar
| University of California, Irvine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LIQUIDIA CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
